Interpretation
This post hoc analysis demonstrated that a higher doses of iTre is associated with an overall greater benefit in patients with PH resulting from ILD, not only in comparison with placebo, but also in comparison with lower doses of iTre. This benefit is magnified when one considers both the prevention of clinical worsening and the attainment of clinical improvement. These results support the importance of early initiation and uptitration of iTre therapy to ≥ 9 bps four times daily. Our analysis lays the foundation for an improvement end point in clinical trials of PH resulting from ILD, thereby raising the bar to meet what patients with PH resulting from ILD hope for and deserve.